Einloggen

Thematische Bibliographien / Trials / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Trials.

Zeitschriftenartikel zum Thema „Trials“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Trials" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Rujuta, Saksena, and M. Mehnert Janice. "Ignorance is not bliss: The importance of publishing negative trials." Biohelikon 2, no. 1 (2014): 1–3. https://doi.org/10.5281/zenodo.814311.

Der volle Inhalt der Quelle

Annotation:

It is not surprising that, in medicine, positive trials tend to generate more excitement compared with negative trials. Positive studies may be perceived as more likely to change the scope of one’s clinical practice. In general, negative studies attract less attention from different parties, including authors, editors, peer-reviewers, physicians, and readers of medical literature. Indeed, industry sponsors and principal investigators may hesitate to publish negative studies if critical acclaim of the work is not anticipated.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Van Der Weyden, Martin B. "Trials on trial." Medical Journal of Australia 175, no. 5 (2001): 241. http://dx.doi.org/10.5694/j.1326-5377.2001.tb143553.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Nelson, Mark. "Trials on trial." New Scientist 209, no. 2800 (2011): 30. http://dx.doi.org/10.1016/s0262-4079(11)60384-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Vulto, Arnold G. "Clinical trials on trial." European Journal of Hospital Pharmacy 19, no. 4 (2012): 347. http://dx.doi.org/10.1136/ejhpharm-2012-000180.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Karki, Naresh. "â€œSolidarity Trialâ€: A Feeling of Trust Towards COVID-19 Treatments." Journal of Lumbini Medical College 8, no. 1 (2020): 164–65. http://dx.doi.org/10.22502/jlmc.v8i1.335.

Der volle Inhalt der Quelle

Annotation:

Corona Virus Disease (COVID-19) drugs are not being developed at the pace in which the disease is spreading throughout the world. WHO and its partners have announced the worldwide clinical trial on 18th March 2020, known as â€œSolidarity Trialâ€ for greater co-ordination of developments of drugs. â€œSolidarity Trialis an international clinical trial to help find an effective treatment for COVID-19â€. The trial is randomized, open-label and adaptive. This trial will analyze four treatment options against standard of care, after recruiting patients from various countries, and then will approac

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Foster, Henry H. "TRIAL MARRIAGES AND DIVORCE TRIALS." Family Court Review 11, no. 1 (2005): 1–7. http://dx.doi.org/10.1111/j.174-1617.1973.tb01183.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Harman, Chloë. "Putting clinical trials on trial." Nature Reviews Nephrology 5, no. 6 (2009): 301. http://dx.doi.org/10.1038/nrneph.2009.89.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

MIZUSHIMA, YUTAKA. "New trials of trial cases." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 29, no. 1/2 (1998): 1–6. http://dx.doi.org/10.3999/jscpt.29.1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Palca, J. "Government ddI trials on trial." Science 246, no. 4935 (1989): 1244. http://dx.doi.org/10.1126/science.2511632.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Moyé, Lemuel A., and Anita Deswal. "Trials within Trials." Controlled Clinical Trials 22, no. 6 (2001): 605–19. http://dx.doi.org/10.1016/s0197-2456(01)00180-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Weinberg, Jeffrey. "Clinical Trials in Progress: ROADS Trial." ONCOLOGY, no. 3508 (August 2021): 495. http://dx.doi.org/10.46883/onc.2021.3508.0495.

Der volle Inhalt der Quelle

Annotation:

Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Dean, Rachel S. "Veterinary clinical trials are on trial." Veterinary Record 181, no. 8 (2017): 193–94. http://dx.doi.org/10.1136/vr.j3867.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Ranganathan, Priya, Vishal Deo, C. S. Pramesh, and Mahesh P. Parmar. "Novel trial designs: Master protocol trials." Perspectives in Clinical Research 16, no. 1 (2024): 50–53. https://doi.org/10.4103/picr.picr_214_24.

Der volle Inhalt der Quelle

Annotation:

Abstract Conventional trial designs are resource and time-intensive. To accelerate the process of testing new interventions, we now have several novel research trial designs. This article focuses on master protocol trials, which allow several therapies to be tested within a single larger trial.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Rokhsefat, Sana, Deanna E. Morra, Martin Offringa, Lisa M. Askie, and Lauren E. Kelly. "Trial registration in pediatric surgery trials." Journal of Pediatric Surgery 53, no. 7 (2018): 1273–79. http://dx.doi.org/10.1016/j.jpedsurg.2017.10.049.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Curtis, John J., and Bruce Kaplan. "Transplant Immunosuppressive Drug Trials on Trial." American Journal of Transplantation 4, no. 5 (2004): 671–72. http://dx.doi.org/10.1111/j.1600-6143.2004.00474.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Graham, H. Kerr. "The trials of trials." Developmental Medicine & Child Neurology 49, no. 3 (2007): 163. http://dx.doi.org/10.1111/j.1469-8749.2007.00163.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Prashant, Singar* Apurva Torane Mayur Paithankar Anuja Jadhav Sakshi Shahane. "The Importance of Clinical Trials in New Drug Design." International Journal of Pharmaceutical Sciences 2, no. 11 (2024): 530–41. https://doi.org/10.5281/zenodo.14062794.

Der volle Inhalt der Quelle

Annotation:

Clinical exploration is an elective wording used to portray clinical examination. Clinical exploration includes individuals, and it is for the most part completed to assess the viability of a helpful medication, a clinical/careful strategy, or a gadget as a piece of treatment and patient administration. In addition, any exploration that assesses the parts of an infection like the side effects, risk factors, and pathophysiology, among others may be named clinical examination. Notwithstanding, clinical preliminaries are those reviews that evaluate the capability of a restorative medication/gadge

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Patel, Khushru. "Envisioning Data in Clinical Trials." International Journal of Science and Research (IJSR) 11, no. 9 (2022): 1068. http://dx.doi.org/10.21275/sr22926130141.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Santhosh R Divya, Samuel. "In Silico Clinical Trials - Review." International Journal of Science and Research (IJSR) 12, no. 6 (2023): 262–66. http://dx.doi.org/10.21275/sr23512133636.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

de Vries, Ymkje Anna, Annelieke M. Roest, Erick H. Turner, and Peter de Jonge. "Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials." Psychological Medicine 49, no. 12 (2018): 2020–26. http://dx.doi.org/10.1017/s0033291718002805.

Der volle Inhalt der Quelle

Annotation:

AbstractBackgroundPrevious studies on reporting bias generally examined whether trials were published in stand-alone publications. In this study, we investigated whether pooled-trials publications constitute a specific form of reporting bias. We assessed whether negative trials were more likely to be exclusively published in pooled-trials publications than positive trials and examined the research questions, individual trial results, and conclusions presented in these articles.MethodsData from a cohort of 105 randomized controlled trials of 16 antidepressants were extracted from earlier public

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Seow, Hsien-Yeang, Patrick Whelan, Mark N. Levine, et al. "Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?" Journal of Clinical Oncology 30, no. 13 (2012): 1456–61. http://dx.doi.org/10.1200/jco.2011.37.2698.

Der volle Inhalt der Quelle

Annotation:

Purpose Many oncology clinical trials departments (CTDs) are in serious fiscal deficit and their sustainability is in jeopardy. This study investigates whether the payment models used to fund industry versus cooperative group trials contribute to the fiscal deficit of a CTD. Methods We examined the lifetime costs of all cooperative group and industry trials activated in the CTD of a cancer center between 2007 and 2011. A trial's lifetime is defined as being from the date the first patient was accrued until the last patient's actual or projected final follow-up visit. For each trial, we calcula

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Hughes, Emily, Tamara Van Bakel, Ashley Raudanskis, et al. "Comparing the Clinical Trial Characteristics of Industry-Funded Trials and Non Industry-Funded Trials." Journal of Law, Medicine & Ethics 52, no. 3 (2024): 693–700. https://doi.org/10.1017/jme.2024.135.

Der volle Inhalt der Quelle

Annotation:

AbstractWe compared study characteristics of randomized controlled trials funded by industry (N=697) to those not funded by industry (N=835). RCTs published in high-impact journals are more likely to be blinded, more likely to include a placebo, and more likely to post trial results on ClinicalTrials.gov. Our findings emphasize the importance of evaluating the quality of an RCT based on its methodological rigor, not its funder type.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Zarin, Deborah A., and Robert M. Califf. "Trial Reporting and the Clinical Trials Enterprise." JAMA Internal Medicine 181, no. 8 (2021): 1131. http://dx.doi.org/10.1001/jamainternmed.2021.2041.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Abd alamir, Moshrik, Susan S. Ellenberg, Ronald S. Swerdloff, et al. "The Cardiovascular Trial of the Testosterone Trials." Coronary Artery Disease 27, no. 2 (2016): 95–103. http://dx.doi.org/10.1097/mca.0000000000000321.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Pardini, Matteo, Gary Cutter, and Maria Pia Sormani. "Clinical trial design for progressive MS trials." Multiple Sclerosis Journal 23, no. 12 (2017): 1642–48. http://dx.doi.org/10.1177/1352458517729461.

Der volle Inhalt der Quelle

Annotation:

The design of clinical trials is a key aspect to maximizing the possibility to detect a treatment effect. This fact is particularly challenging in progressive multiple sclerosis (PMS) studies due to the uncertainty about the right target and/or outcome in phase-2 studies. The aim of this review is to evaluate the current challenges facing the design of clinical trials for PMS. The selection of patients, the instrumental and clinical outcomes that can be used in PMS trials, and issues in their design will be covered in this report.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Van Roessel, I. M. A. A., N. I. Mazur, S. K. Shah, L. Bont, and R. Van Der Graaf. "Post-trial Access in Maternal Vaccine Trials." American Journal of Perinatology 36, S 02 (2019): S41—S47. http://dx.doi.org/10.1055/s-0039-1691799.

Der volle Inhalt der Quelle

Annotation:

AbstractProvisions for post-trial access (PTA) of the experimental intervention are required before the start of a clinical trial. Although there has been ample attention for PTA in the context of preventive vaccine research, discussions on PTA barely include maternal vaccine trials in which mother–infant pairs are exposed to the intervention. In maternal vaccination trials, specific PTA arrangements are required because pregnancy is transient and PTA may apply to the next pregnancy or the child. In this article, we examine the application and adherence to PTA in the context of maternal vaccin

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Ying, Xiangji, and Stephan Ehrhardt. "Pilot Trial Characteristics, Postpilot Design Modifications, and Feasibility of Full-Scale Trials." JAMA Network Open 6, no. 9 (2023): e2333642. http://dx.doi.org/10.1001/jamanetworkopen.2023.33642.

Der volle Inhalt der Quelle

Annotation:

ImportancePilot trials often lead to study design changes in subsequent full-scale trials. Yet, it remains unclear whether these modifications improve the feasibility of the larger trial.ObjectiveTo compare feasibility estimates between pilot and full-scale trials and identify pilot trial characteristics and modifications associated with equivalent or improved feasibility in the full-scale trial.Design, Setting, and ParticipantsThis cohort study used pilot trials published between January 2005 and December 2018 and their corresponding full-scale trials. PubMed was searched for trials on Februa

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Smigel, K. "The Trials of Prevention Trials." JNCI Journal of the National Cancer Institute 81, no. 15 (1989): 1123–26. http://dx.doi.org/10.1093/jnci/81.15.1123.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

The Lancet. "The trials of tenofovir trials." Lancet 365, no. 9465 (2005): 1111. http://dx.doi.org/10.1016/s0140-6736(05)71850-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Sedgwick, P. "Explanatory trials versus pragmatic trials." BMJ 349, no. 13 3 (2014): g6694. http://dx.doi.org/10.1136/bmj.g6694.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Sibbald, B., and C. Roberts. "Understanding controlled trials: Crossover trials." BMJ 316, no. 7146 (1998): 1719–20. http://dx.doi.org/10.1136/bmj.316.7146.1719.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

McKhann, G. M. "The Trials of Clinical Trials." Archives of Neurology 46, no. 6 (1989): 611–14. http://dx.doi.org/10.1001/archneur.1989.00520420029020.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Munayco-Guillén, Fernando, Hilbert Cevallos-Alvarado, Susy Bazán-Ruiz, Omar Espinoza-Yovera, and Rafael Pichardo-Rodríguez. "Características y tendencias de los ensayos clínicos sobre tratamientos en leucemias: análisis del Registro Peruano de Ensayos Clínicos (1995-2024)." Revista de la Facultad de Medicina Humana 25, no. 1 (2025): 126–32. https://doi.org/10.25176/rfmh.v2025i1.6825.

Der volle Inhalt der Quelle

Annotation:

To describe the characteristics and trends of clinical trials (CTs) on leukemia registered in the Peruvian Clinical Trial Registry (REPEC, by its Spanish acronym), a descriptive study was conducted on CTs registered between 1995 and July 2024. The REPEC database was searched using the term “leukemia.” Included were CTs involving patients with acute or chronic leukemias, regardless of disease stage or prior treatment. Variables analyzed included type of leukemia, trial phase, type of product, sponsor, international registration, type of outcome, and methodological characteristics. Out of 2,058

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Feizabadi, Mansoureh, Fatima Fahimnia, Alireza Mosavi Jarrahi, Nader Naghshineh, and Shahram Tofighi. "Iranian clinical trials: An analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)." Journal of Evidence-Based Medicine 10, no. 2 (2017): 91–96. http://dx.doi.org/10.1111/jebm.12248.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Kuznetsova, Yulia А., and Anna V. Smirnova. "Bulletin of Clinical Studies in Q1 2021." City Healthcare 2, no. 2 (2021): 101–8. http://dx.doi.org/10.47619/2713-2617.zm.2021.v2i2;101-108.

Der volle Inhalt der Quelle

Annotation:

Purpose. To evaluate clinical trials data since January 2021 till March 2021. Materials and methods. The information about clinical trial’s approvals from the state register of medicines of Russian Federation ministry of health website was used as the main source of the original data concerning clinical trials. The register contains all the information relating to clinical trials in Russian Federation. Results. Clinical trials data was analyzed by its type (international, local, bioequivalence), sponsorship (foreign, local), phases and disease areas. Separately COVID-19 clinical trials were co

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Bhatt, Arun. "New clinical trial rules: Academic trials and tribulations." Perspectives in Clinical Research 10, no. 3 (2019): 103. http://dx.doi.org/10.4103/picr.picr_103_19.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Nagele, Peter. "The Importance of Definitive Trials: The VIXIE Trial." Anesthesiology 136, no. 3 (2022): 403–4. http://dx.doi.org/10.1097/aln.0000000000004144.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Schoenfeld, D. "Optimizing phase II clinical trials: novel trial designs." Journal of the Peripheral Nervous System 19, S2 (2014): S18—S20. http://dx.doi.org/10.1111/jns.12081_3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Allen, Mary, Heidi Israel, Kyle Rybczyk, et al. "Trial-Related Discrimination in HIV Vaccine Clinical Trials." AIDS Research and Human Retroviruses 17, no. 8 (2001): 667–74. http://dx.doi.org/10.1089/088922201750236942.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Bousquet, Philippe Jean, Pascal Demoly, Giovanni Passalacqua, G. Walter Canonica, and Jean Bousquet. "Immunotherapy: clinical trials – optimal trial and clinical outcomes." Current Opinion in Allergy and Clinical Immunology 7, no. 6 (2007): 561–66. http://dx.doi.org/10.1097/aci.0b013e3282f1d6a4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Reed, N., and N. Siddiqui. "Trials and tribulations: obstacles to clinical trial recruitment." British Journal of Cancer 89, no. 6 (2003): 957–58. http://dx.doi.org/10.1038/sj.bjc.6601233.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Brady, M. F., J. T. Thigpen, J. B. Vermorken, and M. K. B. Parmar. "Randomised trials in ovarian cancer: trial design considerations." Annals of Oncology 10 (1999): S75—S82. http://dx.doi.org/10.1016/s0923-7534(20)31489-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Simberkoff, Michael S. "A tale of two vaccine trials: Trial 1." Current Infectious Disease Reports 4, no. 3 (2002): 235. http://dx.doi.org/10.1007/s11908-002-0084-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Simberkoff, Michael S. "A tale of two vaccine trials: Trial 2." Current Infectious Disease Reports 4, no. 3 (2002): 236–37. http://dx.doi.org/10.1007/s11908-002-0085-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Whitehead, John, Anne Whitehead, Susan Todd, Kim Bolland, and M. Roshini Sooriyarachchi. "Mid-trial design reviews for sequential clinical trials." Statistics in Medicine 20, no. 2 (2001): 165–76. http://dx.doi.org/10.1002/1097-0258(20010130)20:2<165::aid-sim649>3.0.co;2-a.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Millar, Courtney, Kathryn Baldyga, Ikechukwu Iloputaife, Alex Wolfe, Jasmin Kuo, and Lewis Lipsitz. "TRIALS AND TRIBULATIONS OF CONDUCTING A GEROSCIENCE TRIAL." Innovation in Aging 7, Supplement_1 (2023): 1144. http://dx.doi.org/10.1093/geroni/igad104.3673.

Der volle Inhalt der Quelle

Annotation:

Abstract Emerging trials of geroscience interventions show great promise in preventing age-related diseases and disabilities. However, there are many challenges that need to be considered when conducting such trials. Our objective is to describe the major challenges when conducting a geroscience intervention, utilizing the STAMINA study as an example. The STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging) study is a single-arm geroscience-motivated pilot study in which 12 older adults with mild cognitive impairment and slow gait speed are asked to take 12 d

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Qureshi, Riaz. "Overview of clinical trials: trial designs and reporting." Biomedical & Life Sciences Collection 2025, no. 3 (2025): e1006740. https://doi.org/10.69645/dzyh5628.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Qureshi, Riaz. "Overview of clinical trials: history and trial elements." Biomedical & Life Sciences Collection 2025, no. 3 (2025): e1006715. https://doi.org/10.69645/iizg8884.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Frizell, John. "Trials." Nature 509, no. 7501 (2014): 526. http://dx.doi.org/10.1038/509526a.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Ramamurthy, NV. "Inept media trials of clinical trials." Perspectives in Clinical Research 3, no. 2 (2012): 47. http://dx.doi.org/10.4103/2229-3485.96442.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!